DOCSLIB.ORG

How to Ensure Political Commitment for Mdr Tb Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

HOW TO ENSURE POLITICAL COMMITMENT FOR MDR TB MANAGEMENT César Bonilla MD. REGION OF THE AMERICAS TUBERCULOSIS, YEAR 2004 Canada 9% USA Haiti Dom. Rep. Mexico 6.8% Honduras 75% Ecuador Total: 247,387 Peru Bolivia Brazil Peru 50% Nicaragua Brazil Source: WHO Report 2006. Global Tuberculosis Control. Surveillance, Planning, Financing BASIC PRINCPLES IN MDR-TB MANAGEMENT 1. To establish a National TB Program that is efficient, effective and integrated into general health care services 2. To assure free access to quality medication (through application to the Green Light Committee). 3. To coordinate with the community and local governments to establish strategies that help ensure treatment adherence of the TB patient. 4. To provide free access to drug sensitivity tests. 5. To design an appropriate TB treatment regimen for the patient. POSITIONING THE NATIONAL TB CONTROL PROGRAM AS A FUNDAMENTAL ELEMENT IN ENSURING POLITCAL COMMITMENT TECHNICAL EFFICIENCY IN MDR-TB MANAGEMENT 1. Clear objectives for the 6. Coordination and strategic short, medium, and long partnerships that facilitate term. a leadership role of MDR-TB 2. Clear components that management in the health improve processes care reform process, especially in regards to 3. Consistency in application Cross-sectional decentralization. of the DOTS strategy Approach: 4. Transparency in decision- 7. Organizational aspects: POLITCAL making and in the use of Laboratory conditions COMMITTMENT resources Treatment strategy 5. Work in a multidisciplinary Information system and team at different levels of data management health care. Supervision and monitoring of patient care PRODUCTS OF THE APPROPRIATE APPLICATION OF THE BASIC PRINCIPLES IN MDR-TB MANAGEMENT 1. Reliable distribution of medication. 2. Professional commitment, commitment at health care establishments, and experience in MDR-TB patient care that Cross-sectional helps ensure treatment adherence. Approach: 3. Implementation of reliable sensitivity tests POLITCAL for first- and second-line drugs. COMMITTMENT 4. Availability of human and physical resources. STEP-BY-STEP BUILDING OF POLITICAL COMMITMENT IN MDR-TB MANAGEMENT 1. Explanation of the causes of MDR-TB. 2. TB Control: • Towards our intended direction. • DOTS strategy, the right way. 3. Magnitude of the MDR-TB problem. 4. Intervention strategies. • Positioning. • Marketing and Merchandizing. • Strategic partnerships with the civil society and TB patient organizations. • Advocacy, social mobilization, and strategic communication. • Technical efficiency in resource utilization. • Investigation: operational, epidemiological, and clinical. 5. Consolidating political commitment. 1.EXPLAINING THE CAUSES OF MDR-TB MAGNITUDE OF THE MDR-TB PROBLEM IN PERU CHILDREN < 18 YEARS OLD WITH MDR-TB THAT HAVE ACCESS TO STANDARD AND INDIV. RETREATMENT, The presence of MDR-TB is the THREE-YEAR TREND LINE result of numerous failures by PERU 1996-2004 the health care system over 300 time: 1. Use of ineffective treatment regimes for MDR-TB during the 250 80’s and 90’s amplified y = 26,8x - 53,778 resistance. R2 = 0,9352 2. Persistent MDR-TB cases in the 213 community without timely 200 access to adequate treatments MDR-TB increased sources of infection 173 with MDR bacilli among the population. 150 3. Poorly defined therapeutic 124 policies in regards to new MDR- of children with 100 TB cases among contacts of 92 documented MDR-TB cases. Nº < 18 years Trend line (< 18 y) 4. Underestimation of the 56 magnitude of MDR-TB resulted 50 in inadequate diagnosis and 32 treatment interventions. 26 5 0 1 96 97 98 99 00 01 02 03 04 2. TB CONTROL IN PERU: • TOWARDS OUR INTENDED DIRECTION • DOTS STRATEGY THE RIGHT WAY TB MORBIDITY AND INCIDENCE RATES IN PERU, 1990-2005 EpidemiPicoolog ical IniciStarto of de Ref Reformaorm GestManaiógementn y 300 EpidemiolPeak ógico DOTS ExpansiDOTS Expansión y Sostenibon and ilidadSustainab DOTSility anyd Perdida Loss of de Recuperaciand Recoveryón LeaderLidershipazgo deof Leadeliderazgorship 250 200 150 100 EpidemioloPico gical EpidemiolPeakógico 50 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 MORBILIDADMORBIDITY 198,6 202,3 256,1 248,6 227,9 208,7 198,1 193,1 186,4 165,4 155,6 146,7 140,3 123,8 124,4 129,0 INTBCID. INCID. TBC 183,3 192 243,2 233,5 215,7 196,7 161,5 158,2 156,6 141,4 133,6 126,8 121,2 107,7 107,7 109,7 INBKCID.+ IN CID.BK+ 116,1 109,2 148,7 161,1 150,5 139,3 111,9 112,8 111,7 97,1 87,9 83,1 77,4 68,8 66,4 67,1 Source: National Health Strategy for TB Prevention and Control-DGSP/MINSA WHAT ARE WE LOOKING FOR IN MODERN PUBLIC HEALTH? Equity Efficiency Quality What is the target Human population? Guarantee good Resources use of the HR Clergy Collective To whom are we obligated? Health Management of Individual Services PLANNING EXECUTION Health What are the priorities when Avoid overlapping Sustainability considering the situation at each management level? of duties Social Participation PUBLIC HEALTH AND TB CONTROL PROGRAMS State Policies HOW TO CONFRONT THE CURRENT SCENARIO HUMAN RESOURCES EQUIPMENT INFRASTUCTURE GLOBAL CONTEXT • Aging of the population • Increase in public expectations • Globalization • Advances in science and knowledge • Epidemiological change • New demands in regards to learning POLICY GUIDELINES FOR THE HEALTH CARE SECTOR AND THE NATIONAL HEALTH STRATEGY FOR TB PREVENTION AND CONTROL Continuous QualityImprovement DOTS Supply and Rational Use of Drugs DOTS PLUS Technical Ef Sector Management Health HR Prevention Funding Technologic. Comprehensive MINSA and Developm. Care Promotion Democratization Decentralization ficiency Modernization Institutional Comprehensive Local Culture HIV/TB Insurance Governments Strategic Accreditation PAL Partnerships HRTAs PPM Service Others HRTA: High Risk AMSC Training Advocacy, of Transmission Evaluation Areas Social Research Supervision Mobilization Biosafety Monitoring Multidisciplinary, Multifunctional, Intersectorial and Interinstitutional Team Public Health Technical Strategic and Specialization Management Epidemiology Criteria STOP TB Committee Peru National Multisectorial • Coordination, Administration, National Health Strategy for Communication, Cooperation. Health TB Prevention and Control Coordinator • Shared management, leadership and accountability. TB/HIV Co- Infection Committee Group of Experts Scientific Associations Civil Society ComitéTECHNICALTécnic o ADVISORY NGOs PermanenteSTANDING COMMITTEE COMMITTEE Universities MINSA EsSALUD Representatives & Departments Dep. of Health Technical Strategies and Criteria, Strategies, Plans and Criteria Programs Commitments Public Stakeholders (Citizens) Citizen Watch National Health Strategy for Institutional and MINSA TB Prevention Intersectorial and Articulation Control Comprehensive Institutional Stakeholders Care AND Intersectorial Stakeholders TB CONTROL ATTITUDES AND COMMITMENTS 1. Promotion of a health culture in the context of TB control, considering the impact of TB on the person and the society. 2. Personal dignity & bioethical behavior. 3. Promotion & social participation as an expression of active citizenship. 4. Evidence-based information to guide social, technical & political interventions. NEW PARADIGMS 1. Promoting TB and MDR-TB control while preserving human dignity, bioethics, and human rights within a healthy citizen context. 2. Comprehensive and integrated health care to enhance TB and MDR- TB control actions. 3. Promoting advocacy and guiding public policy through intersectoriality, interinstitutionality and development of strategic partnerships for TB and MDR-TB control. 4. Organizing and providing care to people with TB and MDR-TB through multidisciplinary teams comprised of a healthcare team, civil society representatives, and associations of people living with TB. 5. Strategic communication. 4. MAGNITUDE OF THE MDR-TB PROBLEM INITIAL RESISTENCE OF MDR-TB (Americas, 1994-2002) CAN 1.2% USA 1.2% MEX DOM REP 6.6% CUBA 0.3% 3 estadostates s2.4% 2.4% PR 2.5% GUA 3.7% HON 1.8% ELS 0.3% VE 0.3% >= 4 HOT SPOTS NIC 1.2% CO 1.47% WITH MDR ECU 5.0% 0.9% PER 3.0% Bo 1.2% Ch 0.6% (MDR-TB >= 3%) Ar Ur 0.01% (MDR-TB < 3%) 1.8% (MDR-TB =< 1%) No data Sources: PAHO DRUG-RESISTANT TB IN DRUG-RESISTANT TB IN NEW PREVIOUSLY TREATED PATIENTS, PATIENTS, WHO/UICTER 1999 WHO/UICTER 1999 25 23.3 23.5 %20 17.8 WORLD 20 WORLD PERU 15 PERU 15 % 10.7 % 12.3 10 9.3 10 5 3 5 1 0 0 DR TB MDR TB DR TB MDR TB Fuente: WHO/IUATLD. Anti-tuberculosis drug-resistance in the world. Report Nº2. Prevalence and trends. DRUG-RESISTANT TB IN PREVIOUSLY TREATED PATIENTS, WHO/UICTER 1999 25 23.3 23.5 % WORLD 20 PERU 15 12.3 9.3 10 5 0 DR TB MDR TB Fuente: WHO/IUATLD. Anti-tuberculosis drug-resistance in the world. Report Nº2. Prevalence and trends. CHILDREN WITH MDR-TB <18 YEARS THAT CONSENTED TO STANDARD AND INDIVUDUALIZED RETREATMENT, TREND LINE AT THREE YEARS. PERU 1996-2004 300 250 y = 26,8x - 53,778 R 2 = 0,9352 213 200 MDR-TB th 173 wi 150 dren l 124 chi of 100 92 Nº < 18 years Trend line (< 18 años) 56 50 32 26 5 0 1 1996 1997 1998 1999 2000 2001 2002 2003 2004 5. MDR-TB INTERVENTION STRATEGIES METHODOLOGICAL FOUNDATIONS AND IMPACT OF MDR-TB CONTROL Bacteriological “Fitness” of the etiological agent Microorganism Phenomenon of genetic mutation of M-TB Identification of probable cases and Clinical clinical presentation. Individual Diagnostic and therapeutic methods. Epidemiology of MDR-TB Epidemiological Community Identification of high risk areas Operational Intervention strategies Control Control principles POINT OF EQUILIBRIUM OR RUPTURE OF BALANCE Control Strategies M.TB Resistant M. TB Sensitive DOTS PLUS Treatment DOTS Prevention MULTI-DRUG RESISTANT TUBERCULOSIS ORIGIN OF MDR-TB DOTS Human error Bad treatments Responsibility of the health care system & the Medical responsibility ESNC-TB Administration of inadequate Logistics of inadequate Inadequate treatment treatment chemotherapy Uninformed patient Unsupervised treatment DOTS PLUS ACQUIRED RESISTANCE PRIMARY RESISTANCE AmericanThoracic Society/CDC. Treatment of tuberculosis infection in adults and children. Am Resp Crit Care Med 1994;149:1359-1374 FOCUS ON MDR-TB CONTROL WITHIN THE CONTROL PROGRAM PLANS 9 Adequate therapeutic arsenal.
Recommended publications
  • World TB Day 2001 Highlights [.Pdf]

    World TB Day 2001 Highlights [.Pdf]

    HIGHLIGHTS_RET POUR PDF 17/10/01 11:34 Page 1 GUIDELINES for SOCIAL MOBILIZATION World TB Day 2001 Highlights Political Awareness Social Mobilization Increased Access to TB Care Sustainability Media and Community Events Best Practice HIGHLIGHTS_RET POUR PDF 17/10/01 11:34 Page 2 Preface p.5 Political Awareness Pakistan Australia United States India, Punjab Democratic Republic of the Congo Yemen he theme for World TB Day 2001— p.9 Social Mobilization T DOTS: TB cure for all—suggests that Oman we can eliminate tuberculosis from this Togo planet. A cure for all from tuberculosis (TB) is part Nigeria of the mission of the World Health Organization 3 India, Mumbai (WHO) and its Member States to allow access to The former Yugoslav Republic health services for all. of Macedonia Albania A first milestone occurred when Ministers of ACKNOWLEDGEMENT: Federal Republic of Yugoslavia Health, Development, and Finance Planning from Haiti 20 countries with the highest burden of TB met in Slovakia Amsterdam in March 2000 for the first summit THE STOP TB PARTNERSHIP WOULD LIKE TO THANK THOSE Maldives WHO TOOK THE TIME TO COMPLETE THE WORLD TB DAY against tuberculosis. 2001 QUESTIONNAIRE AND TO SUBMIT TO US REPORTS AND p.15 Increased Access Great progress has since been made as a result of ILLUSTRATIONS ABOUT THEIR ACTIVITIES. to TB Care the mobilization of the high TB burden countries India: supported by the international community as a Andhra Pradesh Rajasthan whole. This was reflected in World TB Day on 24 Tamil Nadu March 2001. Bihar This document brings to the fore the Uttar Pradesh accomplishments of World TB Day 2001, reports on Lebanon what has been achieved, underlines the remarkable Philippines events and initiatives, and analyses how the global p.19 Sustainability movement to stop TB is progressing towards its India goal of eliminating TB as a global public health Russian Federation problem.
  • Division of Disease Control Pump Handle - 1

    Division of Disease Control Pump Handle - 1

    "I had an interview with the Board of Guardians of St. James's parish, on the evening of Thursday, 7th September, and represented the above circumstances to them. In consequence of what I said, the handle of the pump was removed on the following day." John Snow, 1855 February 2015 Topics Avian Influenza (Bird Flu) in the United States April is STD Awareness Month Find TB. Treat TB. Working together to eliminate TB. Disease Control Student Interns-Welcome! Avian Influenza (Bird Flu) in the United States In December of 2014, a handful of western U.S. states reported the identification of several high pathogenic avian influenza A H5 strains in local birds, including H5N1, H5N2 and H5N8. Since the initial reports, a total of 10 states have identified influenza A H5 strains in wild or domestic birds: Washington, California, Idaho, Oregon, Utah, Nevada, Minnesota, Missouri, Arkansas and Kansas. These H5 strains are genetically different than the H5 strains currently circulating in Asia and Africa, but are similar to strains identified this past December in British Columbia, Canada. No human cases have been associated with these U.S. avian influenza strains at this time. Avian influenza strains are not easily transmitted from birds to humans, and the risk to humans is currently considered extremely low. However, health care providers should consider avian influenza in people with influenza-like illness who have been in contact with sick or dead birds (especially poultry or water fowl) in the previous 10 days. Suspected cases of avian influenza should be reported immediately the to the North Dakota Department of Health (NDDoH) Division of Disease Control to discuss the exposure, antiviral recommendations and diagnostic testing.
  • Advancing New Diagnostic Tests for Latent Tuberculosis Infection

    Advancing New Diagnostic Tests for Latent Tuberculosis Infection

    International Journal of Infectious Diseases 92S (2020) S69–S71 Contents lists available at ScienceDirect International Journal of Infectious Diseases journal homepage: www.elsevier.com/locate/ijid Advancing new diagnostic tests for latent tuberculosis infection due to multidrug-resistant strains of Mycobacterium tuberculosis — End of the road? a b c,d e,f Peter Mwaba , Jeremiah Muhwa Chakaya , Eskild Petersen , Christian Wejse , g h,i, Alimuddin Zumla , Nathan Kapata * a Apex University School of Medicine, and UNZA-UCLMS Research and Training Program, Lusaka, Zambia b Department of Medicine, Kenyatta University, Nairobi, Kenya c Directorate General for Disease Surveillance and Control, Ministry of Health, Muscat, Oman d Institute for Clinical Medicine, Faculty of Health Science, University of Aarhus, Aarhus, Denmark e Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark f Center for Global Health, Department of Health Services Research, Aarhus University, Aarhus, Denmark g Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, and NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom h UNZA-UCLMS Research and Training Program, University Teaching Hospital, Lusaka, Zambia i Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia A R T I C L E I N F O A B S T R A C T Article history: An estimated 1.8 billion people worldwide have a latent tuberculosis infection (LTBI), with wide Received 26 January 2020 variations in LTBI rates across countries. LTBI can be due to infection with either drug-sensitive or drug- Received in revised form 9 February 2020 resistant Mycobacterium tuberculosis (Mtb) strains.
  • HIV-TB Comorbidity – Current Challenges and Strategies“

    HIV-TB Comorbidity – Current Challenges and Strategies“

    In cooperation with: WHO-Euro, Copenhagen; Stop TB Partnership; Stop TB Forum Germany, Berlin; Charité University Medicine, Berlin; Central Tuberculosis Research Institute, Moscow, Russia; Institute for Public Health, Ministry of Health, Moscow, Russia; Institutes or departments for Tuberculosis in Smolensk, Voronezh, Yekaterinburg, Russia; Institute for Phthisiopulmonology Chiril Draganiuc, Moldova; Institute for Tuberculosis, Tbilisi State Medical University, Georgia. Eighth Scientific Symposium on the occasion of World Tuberculosis Day 2014 Partners: Berlin Becton Dickinson Diagnostics, Hain Lifescience, vfa, Otsuka Program „HIV-TB comorbidity – current challenges and strategies“ March 20 th – 21 st , 2014 In 2014, the Koch-Mechnikov-Forum organizes the tuberculosis symposium on Langenbeck-Virchow-House, Luisenstr. 59, occasion of the World Tuberculosis Day in close cooperation with the World D – 10117 Berlin, Germany Health Summit. Its results will be reported and discussed at the next World Health Summit in Berlin, held in October 2014. in close cooperation with Content: Both, HIV and Mycobacterium tuberculosis , belong to the biggest killers and Venue: Langenbeck-Virchow-Haus, Luisenstr. 59, 10117 Berlin, Germany account for millions of deaths year by year. In recent years, coinfection with both Time: pathogens not only occurs in Subsaharan Africa, but also at tremendously Thursday, March 20, 2014: opening, first scientific day; reception; increasing speed in Eastern Europe and Central Asia where the problem of Friday, March 21, 2014: scientific symposium, second scientific day multidrug-resistant tuberculosis already makes an efficient tuberculosis control virtually impossible. Although the development of new strategies, new diagnostic Certification: tools and new drugs to fight tuberculosis is currently speeding up, HIV-TB acquirable: Continuing education credit points 12 (Category A).
  • World TB Day Reminds Us to Remain Vigilant

    World TB Day Reminds Us to Remain Vigilant

    March 21, 2013 Contact: Tom Schlueter (630) 444-3098 (630) 417-9729 cell World TB Day reminds us to remain vigilant On World Tuberculosis Day, March 24, the Kane County Health Department is reminding people that, although the illness is not as common as it once was, it is still circulating around the world. World TB Day commemorates the day in 1882 when Dr. Robert Koch announced his discovery of the bacteria that causes TB, Mycobacterium tuberculosis. TB has been a scourge across human history, and the discovery of the causative agent by Dr. Koch began the modern public health efforts to control and now, eliminate, TB. The Kane County Health Department has been battling an outbreak of TB at a local homeless shelter since 2007. While TB cases statewide in Illinois have reached record lows, a total of 45 cases of active TB have been linked to the shelter outbreak. Health Department nurses visit the shelter daily as the investigation continues. Tuberculosis is a contagious and potentially life-threatening disease that is transmitted from person to person through the air when a person with active TB coughs or sneezes. While it can affect any part of the body, such as the brain, kidneys or spine, tuberculosis usually affects the lungs. General symptoms may include fatigue, weight loss, fever and night sweats. When tuberculosis attacks the lungs, symptoms can include a persistent cough that sometimes produces blood and chest pains. While tuberculosis is usually curable, a person with the disease must faithfully adhere to prescribed drug therapy for six months or longer.
  • Igras: Among the Blind the One-Eyed Is King 2Nd Symposium About Igras Special Session World Tuberculosis Day

    Igras: Among the Blind the One-Eyed Is King 2Nd Symposium About Igras Special Session World Tuberculosis Day

    IGRAs: Among the blind the one-eyed is king 2nd symposium about IGRAs Special Session World Tuberculosis Day. 21st of March 2013 Barcelona. Catalonia. Spain J. Domínguez Servei Microbiologia. Institut d’Investigació Germans Trias i Pujol Badalona, Barcelona. ([email protected]) Brief history 2000 Nil Avian Human Mitogen Control PPD PPD Control Stimulating antigens: human PPD and avian PPD Brief history T-SPOT.TB Tuberculin skin testing QuantiFERON-TB Gold In Tube 2002 Moving LTBI diagnosis from clinical departments to laboratory. Comparison between TST and IGRAs Domínguez J. Actas Derm-Sifil. 2012 Domínguez J. 2009 First day T-SPOT.TB QFN-G-IT Exp Rev Resp Med. Collection of blood sample (8ml) Collection of blood sample and centrifugation (3ml) in QFN tubes containing MTB antigens Isolation of PBMCs and washing hands No Count PBMCs using a - on time for 1 sample for 1 on time on time - counting chamber on time for 20 samples 20 on time for - Addition of 250,000 cells per well 4 h hands 4 with the MTB specific antigens 1/2 hour (h) hands (h) hour 1/2 Overnight incubation Overnight incubation Second day Centrifugation of tubes to harvest the IFN-gamma released samples 20 to 1 for 1 h hands h 1 on for time ELISPOT ELISA - - on time 1 to 20 samples samples 20 to 1 1 h hands h 1 Count spots by naked eye or using a plate reader Read the concentration of IFN-gamma by means of an automated reader Correlation with latent TB infection Domínguez J. CVI. 2008 BCG vaccination effect Domínguez J.
  • Discurso De La

    Discurso De La

    Address of Dr. Carissa F. Etienne at the World Tuberculosis Day commemoration “Stop TB in our lifetime. A Shared Commitment” Washington D.C., March 19, 2013 Good morning. We mark World Tuberculosis Day today in commemoration of Dr. Robert Koch, who, on the 24th of March 1882, announced to the world the discovery of the disease’s causative agent, the “tubercle bacillus.” Although 130 years have come and gone since then, tuberculosis continues to be responsible for pain and death across the globe, not excluding the Americas. This year we celebrate World TB Day with the slogan “STOP TB IN OUR LIFETIME. A SHARED COMMITMENT”. This means commitment by all, as affected communities and partners in combating the disease embrace the goal of “ZERO TB DEATHS.” Great progress in controlling tuberculosis has been made in the Americas – so much so that the Millennium Development Goal targets for TB have been met ahead of time, with a stable 3% annual reduction in the incidence of the disease, a 61% reduction in mortality, and a 62% reduction in prevalence between 1990 and 2011. These are major achievements; however, they do not extend to the most vulnerable populations, such as ethnic minorities, and our poor and marginalized populations living in cities. We currently have opportunities, since our Region is experiencing sustained economic growth, with stable governments and major advances in development that have positive impacts for health – as the increased life expectancy of the Region’s inhabitants reflects. The recognition and addressing of the social determinants of health through harmonized and coordinated work across different political and social sectors is allowing better living conditions for the most unprotected populations.
  • Biomérieux Announces the CE Marking of TB IGRA® Test on VIDAS®

    Biomérieux Announces the CE Marking of TB IGRA® Test on VIDAS®

    bioMérieux announces the CE marking of TB IGRA® test on VIDAS® Marcy l’Etoile, France – March 24th, 2021 – Today marks World Tuberculosis (TB) Day and bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its innovative and fully-automated test VIDAS® TB IGRA (Interferon-Gamma Release Assay) to diagnose latent TB infection. Tuberculosis continues to be a major global health problem. With 10 million new active cases and 1.4 million related deaths worldwide in 20191, TB remains an important cause of mortality from a single infectious disease. It is estimated that a fourth of the global population is infected with Mycobacterium tuberculosis, the bacteria responsible for TB disease. In most cases (90-95%), people with healthy immune systems can control the infection without developing the active disease: this is called “Latent Tuberculosis Infection” (LTBI). The remaining infected people (5-10%), will develop active TB disease (aTB), making them sick as well as infectious to others. “Despite all efforts, tuberculosis has not been eradicated and remains a significant health problem for a large proportion of the world’s population, especially in low- and middle-income countries. Diagnosing people who have latent TB infection is an important tool for global TB control. Detecting and then following or treating people with latent TB infection can help in preventing their progression to active disease, which would make them sick and also infectious to others.” said Mark Miller, Executive Vice President and Chief Medical Officer, bioMérieux. There is no single gold standard for diagnosing LTBI. Current diagnostic tools for LTBI include a detailed clinical history of exposure to TB, the tuberculin skin test (TST) or an IGRA test, which are indirect diagnostic methods based on the host immune response to the pathogen2.
  • Timo Ulrichs, KMF, and Akkon University for Human Sciences Berlin

    Timo Ulrichs, KMF, and Akkon University for Human Sciences Berlin

    9th Scientific Symposium on the occasion of World Tuberculosis Day 2015 Berlin Preliminary Program Tuberculosis control and prevention – Vaccination, prophylaxis and public health interventions Aim and content Together with HIV/AIDS and malaria, tuberculosis still belongs to the three big killers of humanity, accounting for approximately 1.5 million deaths per year. Although the millennium development goal number 6 aimed at reducing TB numbers by 50% in 2015 compared to the situation in 1990, TB is still a global health emergency. Especially in the WHO European Region, we are far away from reaching MDG No. 6, and this has to be discussed in detail after analyzing the situation in 2015, the endpoint of the MDG time frame. Two major obstacles prevented us from improving the situation: increasing numbers in multidrug-resistant cases and HIV-TB comorbidity. Successful treatment of these cases becomes more and more impossible. Thus, preventive strategies and most of all an efficient vaccine are urgently needed. The 9th Scientific Symposium of the Koch-Mechnikov-Forum on the occasion of World Tuberculosis Day 2015 will therefore focus on current developments in vaccine research, preventive and public health measures in TB control and overall strategies to efficiently fight the disease. Organization The 9th Scientific TB Symposium is co-organized by the Koch-Mechnikov-Forum (KMF) and the Tuberculosis Vaccine Initiative (TBVI). 1 Scientific organizing committee: Erna Balk, TBVI, Lelystad, The Netherlands Executive Director, TBVI Helmut Hahn, KMF Berlin Timo Ulrichs, KMF, and Akkon University for Human Sciences Berlin Project coordination: Anastasia Stepanovich, KMF, Langenbeck-Virchow-Haus, Luisenstraße 59, 10117 Berlin, Germany; Tel.: +49-30-2345-7722; [email protected] Venue KARL-STORZ GmbH & Co.
  • World Tuberculosis Day 2019: More Needs to Be Done to #Endtb by 2030

    World Tuberculosis Day 2019: More Needs to Be Done to #Endtb by 2030

    World Tuberculosis Day 2019: more needs to be done to #EndTB by 2030 March 24 marks World Tuberculosis Day. In 1882 on this day, Dr Robert Koch announced the discovery of the bacteria that causes tuberculosis (TB), and paved the way towards diagnosing and treating it. Thanks to years of efforts, better diagnostics tools and more effective treatment regiments give hope to TB patients, their families and communities. Ahead of World Tuberculosis Day, the Commission announced: "On the World Tuberculosis Day taking place on Sunday 24 March, the European Commission aims to raise awareness about the burden and prevention of tuberculosis as well as to mobilise efforts in the fight against the disease. Although every hour, 30 people are diagnosed with tuberculosis in Europe, overall, the decrease in tuberculosis cases observed in most countries is reassuring. Still, sustained efforts are needed to reach the 80% reduction target in the tuberculosis incidence rate in 2030 compared to 2015. Vytenis Andriukaitis, European Commissioner for Health and Food Safety, said: "On World Tuberculosis Day, my thoughts are with all the people who are suffering from the deadliest infectious disease in the world. The EU Member States have reiterated their commitment to end the tuberculosis epidemic by 2030 at a high-level United Nations meeting in September 2018. Therefore, I call on leaders in the EU and beyond, to boost their public health measures against tuberculosis hand in hand with other sectors. Existing tools and good practices should be better implemented, and focus on people's needs. Together with our agencies, the Commission will continue to support such efforts from different policy angles including funding, research, fight against antimicrobial resistance, prevention, early diagnosis and linkage to treatment and care.
  • STANDARD DEVIATIONS: Keeping a Perspective

    STANDARD DEVIATIONS: Keeping a Perspective

    STANDARD DEVIATIONS: Keeping a Perspective Greetings, Coronavirus is all the rage. It dominates our news, our conversations, and our lives. But in terms of consequence to our health and the world, coronavirus is just another drop in the bucket. Tomorrow is World Tuberculosis Day. Each year, we recognize World TB Day on March 24. This annual event commemorates the date in 1882 when Dr. Robert Koch announced his discovery of Mycobacterium tuberculosis, the bacillus that causes tuberculosis (TB). Up to 13 million people in the United States have latent TB infection. Here is a respiratory disease that dwarfs COVID-19. This bacterial malady is spread from person to person through the air. TB usually affects the lungs, but it can also affect other parts of the body, such as the brain, the kidneys, or the spine. The TB bacteria are put into the air when a person with TB disease of the lungs or throat coughs, sneezes, speaks, or sings. People nearby may breathe in these bacteria and become infected. Sound familiar? Worldwide, 10 million people acquired TB in 2018 (last year of stats) and 1.5 M died. Nearly 500,000 cases are drug-resistant type TB. The common tests we utilize these days are the tuberculin skin test that we geezers recall being administered each year by our employee health nurse and read a few days later with a ruler, and the standard now, the QuantiFERON®–TB Gold In-Tube test (QFT–GIT). We also perform a bunch of lab work on these patients. The Acid-Fast Bacillus (AFB), Nucleic Acid Amplification Test (NAAT), and sputum culture all add to our workload.
  • Hawai'i Department of Health Urges Residents to Review Their Risk for TB

    Hawai'i Department of Health Urges Residents to Review Their Risk for TB

    DEPARTMENT OF HEALTH DAVID Y. IGE GOVERNOR ELIZABETH A. CHAR, MD DIRECTOR FOR IMMEDIATE RELEASE March 23, 2021 21-049 Hawai‘i Department of Health urges residents to review their risk for TB as part of annual World Tuberculosis Day on March 24 HONOLULU – It is estimated that one fourth of the world’s population may carry tuberculosis (TB) in its latent or inactive form; placing them at risk for TB disease later in life. No one knows for sure how many people in Hawai‘i have this infection, but the Hawai‘i Department of Health estimates the number could be as high as 70,000 to 100,000 residents. As part of the globally observed World Tuberculosis Day on March 24, the health department is urging Hawai‘i residents who are at risk to get tested for TB infection. Approximately 10 percent of people who are infected with latent TB will go on to develop active TB disease and they could benefit from medication to prevent the development of this infectious and serious illness. Although many people believe that TB is a disease of the past, it has remained a leading killer among infectious diseases worldwide for more than 135 years, according to Dr. Elizabeth MacNeill, Chief of the Department of Health’s Tuberculosis Control Branch. “Hawai‘i residents are particularly vulnerable because of our close ties to areas of the world where TB is more common. Those who travel frequently and spend time in countries where TB occurs or who have close contact with a person with active TB disease are at the greatest risk of being exposed and infected by TB,” MacNeill said.